Author

Rajat Thawani

University of ChicagoORCID 0000-0002-5378-9434Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander Edward Dela Cruz DriloniD· 1 shared Catherine Z. BeachiD· 1 shared Clare KeddyiD· 1 shared Guilherme HaradaiD· 1 shared Katelyn S. NicholsoniD· 1 shared Kevin D. NusseriD· 1 shared Kristen L. JonesiD· 1 shared Matteo Repetto· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander Edward Dela Cruz DrilonORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer Biologynpj Precision OncologyPeer-reviewedAug 8, 2024

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers

Rajat Thawani, Matteo Repetto, Clare Keddy…·Monika Ashok Davare

This study shows that type II TKIs cabozantinib and merestinib, and type I FLT3 inhibitor gilteritinib, inhibit ROS1 L2086F mutant kinase, overcoming resistance to type I TKIs in ROS1 fusion-positive cancers.

13 citations

humanproteomics

𝕏 PostBluesky